Dublin, Dec. 23, 2016 -- Research and Markets has announced the addition of the "Type 2 Diabetes Drugs Price Analysis and Strategies - 2016" report to their offering.
Type 2 Diabetes Drugs Price Analysis and Strategies 2016, provides drug pricing data and benchmarks in the global Type 2 Diabetes market.
The research answers the following questions:
- What are the key drugs marketed for Type 2 Diabetes and their clinical attributes? How are they positioned in the Global Type 2 Diabetes market?
- What are the unit prices and annual treatment cost for Type 2 Diabetes therapies in different countries? What are the drug pricing trends and how are they expected to change in the future? How are the drug pricing and reimbursement landscape different by countries?
- What are the unmet needs in the global Type 2 Diabetes drugs market? What would be the ideal pricing strategy for a new pipeline therapy for Type 2 Diabetes?
Research Scope:
- Treatment Options - Identify key drugs marketed and prescribed for Type 2 Diabetes including trade name, molecule name, and company
- Drugs Attributes - Find out the safety, efficacy, and risk benefit for key drugs marketed for Type 2 Diabetes
- Market Positioning - Identify how drugs are clinically and commercially positioned in the global Type 2 Diabetes market
- Type 2 Diabetes Drugs Price Analysis - Find out the annual therapy cost and unit price for key drugs marketed
- Find out how the price advanced from 2012 and forecast to 2021
- Pricing & Reimbursement Landscape - Find out the pricing and reimbursement landscape
- Type 2 Diabetes New Drug Pricing - Identify the effective pricing strategy for a new drug launch
Key Topics Covered:
1. Treatment Options
2. Drugs Clinical Attributes
3. Drugs Market Positioning
4. Drugs Price Analysis
5. Drugs Price Benchmarks
6. Drug Pricing & Reimbursement Landscape
7. Drugs Price Forecast
8. Market Unmet Needs
9. New Drug Pricing
For more information about this report visit http://www.researchandmarkets.com/research/gnpmx2/type_2_diabetes
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Endocrine and Metabolic Disorder Drugs


Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 



